Search Result

Results for "

transit

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Akt (2) Antibiotic (1) Apoptosis (2) Bacterial (1) Bcl-2 Family (1) Calcium Channel (1) Caspase (1) CFTR (1) Drug Metabolite (2) ERK (1) GABA Receptor (1) GHSR (3) GSK-3 (1) Isotope-Labeled Compounds (1) JNK (1) Keap1-Nrf2 (1) MDM-2/p53 (1) Mitosis (1) NF-κB (1) Opioid Receptor (6) PAK (1) PI3K (2) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) ROR (1) SOD (1) Topoisomerase (1) TRP Channel (1)
By Research Areas:	Cancer (4) Endocrinology (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (9) Neurological Disease (5)

By Targets:

5-HT Receptor (3)

Akt (2)

Antibiotic (1)

Apoptosis (2)

Bacterial (1)

Bcl-2 Family (1)

Calcium Channel (1)

Caspase (1)

CFTR (1)

Drug Metabolite (2)

ERK (1)

GABA Receptor (1)

GHSR (3)

GSK-3 (1)

Isotope-Labeled Compounds (1)

JNK (1)

Keap1-Nrf2 (1)

MDM-2/p53 (1)

Mitosis (1)

NF-κB (1)

Opioid Receptor (6)

PAK (1)

PI3K (2)

Potassium Channel (1)

Reactive Oxygen Species (ROS) (1)

ROR (1)

SOD (1)

Topoisomerase (1)

TRP Channel (1)

By Research Areas:

Cancer (4)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (9)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0118A

Naloxegol oxalate 2 Publications Verification NKTR-118 oxalate; AZ-13337019 oxalate	Opioid Receptor	Metabolic Disease
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target K_i of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .

HY-145404

Mitragynine pseudoindoxyl 1 Publications Verification	Opioid Receptor	Metabolic Disease
Mitragynine pseudoindoxyl is a potent orally active agonist of the μ-opioid receptor (MOR-1, K_i=0.8 nM) and an antagonist of the δ-opioid receptor (DOR-1, K_i=3.0 nM). Mitragynine pseudoindoxyl has moderate affinity for the κ-opioid receptor (KOR-1, K_i=24 nM) and does not recruit β-arrestin-2, acting through G protein-mediated signaling pathways without β-arrestin-2-related activation. Mitragynine pseudoindoxyl produces potent analgesic activity through a mixed μ-agonist/δ-antagonist mechanism, with low side effects such as physical dependence, respiratory depression, and constipation, and no rewarding or aversive behaviors. Mitragynine pseudoindoxyl reduces hyperactivity, inhibits GI transit, and enhances characteristics, making it a potential analgesic .

HY-108229

6β-Naltrexol 6β-Hydroxynaltrexone	Drug Metabolite Opioid Receptor	Neurological Disease
6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-108229S

6β-Naltrexol-d3 6β-Hydroxynaltrexone-d₃	Isotope-Labeled Compounds Opioid Receptor Drug Metabolite	Neurological Disease
6β-Naltrexol-d₃ (6β-Hydroxynaltrexone-d₃) is deuterium labeled 6β-Naltrexol. 6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-N12281

Sennoside	Apoptosis MDM-2/p53 PAK Calcium Channel	Endocrinology Cancer
Sennoside is an orally active apoptosis inducer and stimulant laxative, found in Senna (Cassia angustifolia). Sennoside induces overexpression of wild-type p53 and p21/WAF as part of pathways mediating colonic epithelial cell apoptosis. Sennoside stimulates colonic peristalsis, reverses net water, sodium, chloride absorption to secretion and enhances potassium and calcium secretion. Sennoside increases paracellular permeability to small molecules, accelerates colon transit and softens fecal pellets. Sennoside can be used for the research of constipation, melanosis coli, and colorectal cancer .

HY-135319

Strictinin	Bacterial Antibiotic ERK JNK NF-κB ROR Apoptosis Caspase GSK-3 Akt PI3K	Infection Metabolic Disease Inflammation/Immunology Cancer
Strictinin is an orally active phenolic compound. Strictinin reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in hepatocytes treated with Xanthine (HY-W017389). Strictinin decreases elevated serum uric acid levels and enhanced xanthine oxidase activity in mice treated with potassium oxonate. Strictinin acts as a ROR1 inhibitor and exhibits anticancer activity against highly aggressive non-androgen-dependent prostate cancer. Strictinin induces cancer cell apoptosis (apoptosis), arrests cell cycle, and inhibits cancer cell migration, invasion, and epithelial-mesenchymal transition. Strictinin modulates gut microbiota, inhibits bacterial growth and biofilm formation, accelerates small intestinal transit, and blocks viral entry and replication. Strictinin can be used in research related to hyperuricemia, androgen receptor-negative non-androgen-dependent prostate cancer, triple-negative breast cancer, bacterial infections, constipation, coronavirus infections, dental caries, and infections caused by influenza A, influenza B, and human parainfluenza virus type 1 .

HY-N10144

Shinpterocarpin	PI3K Akt Keap1-Nrf2 Bcl-2 Family SOD Reactive Oxygen Species (ROS)	Inflammation/Immunology
Shinpterocarpin is a flavonoid compound. Shinpterocarpin can be isolated from the air-dried roots of Glycyrrhiza glabra L. and Xuanshen Decoction. Shinpterocarpin binds to the targets PI3K, AKT, Nrf2, Bcl-2, Bax, CAT and SOD. Shinpterocarpin enhances immunity and exerts antioxidant effects by reducing the production of ROS .

HY-A0118

Naloxegol NKTR-118; AZ-13337019	Opioid Receptor	Neurological Disease Cancer
Naloxegol (NKTR-118; AZ-13337019) is an orally active peripherally acting μ-opioid receptor antagonist with a target K_i of 7.42 nM. Naloxegol inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol is applicable to research related to opioid-induced constipation .

HY-178236

TRPM5 agonist-1	TRP Channel	Metabolic Disease
TRPM5 agonist-1 is an orally active TRPM5 agonist with a pEC₅₀ of 8.1. TRPM5 agonist-1 shows excellent selectivity (> 100-fold) versus related cation channels (TRPM8, TRPV1, TRPV4, TRPA1, TRPM4). TRPM5 agonist-1 exhibits locally acting stimulatory effect on gastrointestinal transit in mice. TRPM5 agonist-1 can be used for research on promoting gastric motility .

HY-14495

BMS-604992 EX-1314	GHSR	Metabolic Disease
BMS-604992 (EX-1314) is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 demonstrates high-affinity binding (K_i=2.3 nM) and potent functional activity (EC₅₀=0.4 nM). BMS-604992 can stimulate food intake in rodents .

HY-P3597

Urocortin III (mouse) free acid	CFTR	Others
Urocortin III (mouse) (free acid) is a selective CRF2 receptor agonist (with high affinity for the CRF2 receptor). Urocortin III (mouse) (free acid) significantly inhibits gastric emptying without modifying colonic transit .

HY-U00121A

Lintopride hydrochloride	5-HT Receptor	Metabolic Disease
Lintopride hydrochloride, a benzamide, is a potent 5HT-4 antagonist with moderate 5HT-3 antagonist properties. Lintopride hydrochloride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animal. Lintopride hydrochloride significantly increases the lower oesophageal sphincter (LOS) basal tone .

HY-10919

C-1311	Topoisomerase Mitosis	Cancer
C-1311 shows to inhibit the catalytic activity of DNA topoisomerase II in vitro and in tumour cells. C-1311 prolongs G2 arrest followed by G2 to M transit and cell death during mitosis in the process of mitotic catastrophe .

HY-U00121

Lintopride	5-HT Receptor	Metabolic Disease
Lintopride, a benzamide, is a potent 5HT-4 antagonist with moderate 5HT-3 antagonist properties. Lintopride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animal. Lintopride significantly increases the lower oesophageal sphincter (LOS) basal tone .

HY-118696

MGAT2-IN-5	GABA Receptor	Neurological Disease
MGAT2-IN-5 (Compound 17b) is a selective inhibitor for *mouse GABA transit* protection subsidity 2 (mGAT2) with an IC₅₀ of 45 μM. MGAT2-IN-5 exhibits anticonvulsive efficacy in audiogenic seizure (AGS) susceptible frings mouse model with an ED₅₀** of 20.4 mg/kg .

HY-173131

5-HT4R agonist-2	5-HT Receptor	Others
5-HT4R agonist-2 (Compound 4) is a selective 5-HT4R agonist with an EC₅₀ value of 0.41 nM. 5-HT4R agonist-2 can significantly enhance whole gut and colonic transit, increase fecal output and water content, while maintaining minimal systemic absorption, and it shows promise for the research of chronic idiopathic constipation .

HY-14495A

BMS-604992 free base EX-1314 free base	GHSR	Metabolic Disease
BMS-604992 (EX-1314) free base is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 free base demonstrates high-affinity binding (k_i=2.3 nM) and potent functional activity (EC₅₀=0.4 nM). BMS-604992 free base can stimulate food intake in rodents .

HY-14495B

BMS-604992 dihydrochloride EX-1314 dihydrochloride	GHSR	Metabolic Disease
BMS-604992 (EX-1314) dihydrochloride is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 dihydrochloride demonstrates high-affinity binding (k_i=2.3 nM) and potent functional activity (EC₅₀=0.4 nM). BMS-604992 dihydrochloride can stimulate food intake in rodents .

HY-181103

ERG-IN-6	Opioid Receptor Potassium Channel	Neurological Disease
ERG-IN-6 (compound (+)-(S)-5a) is a μ-opioid receptor activator with an EC₅₀ of 0.12 nM. ERG-IN-6 also is a hERG (Kv11.1) potassium channel inhibitor with an IC₅₀ of 0.681 μM. ERG-IN-6 can be used for the research of pain .

Cat. No.	Product Name

HY-L022M

FDA-Approved Drug Library Mini	3,220 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,220 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

FDA-Approved Drug Library Mini

3,220 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,220 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

Cat. No.	Product Name	Target	Research Area